Kim Bullock, Phd, CCRP
Kim Bullock is Director of the Protocol Development Team for the University of Virginia Cancer Center, Office of Clinical Research and the Human Immune Therapy Center. She specializes in writing and implementing oncology-based, investigator-initiated clinical trials, and provides research support for clinical and research faculty in the Department and the Cancer Center to develop their clinical trial research programs.
Learn More About Protocol Development
Craig L. Slingluff Jr., MD
Dr. Slingluff’s research work includes laboratory studies and clinical trials focused primarily on developing melanoma vaccines and combination immunotherapy with extensive correlative studies. Since 1996, he has led over 30 investigator-initiated clinical trials, most of which have been for melanoma vaccines, especially involving melanoma peptides. These studies have all included intensive immunologic correlates based on evaluating immunologic response in multiple tissue compartments. A major focus of his work now is on characterizing the metastatic melanoma microenvironment, especially including the molecular mediators of immune dysfunction versus tumor rejection. He has published over 190 manuscripts reporting his research, in peer-reviewed journals with high impact, including Science, Science Immunology, Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research and Annals of Surgery.